Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug:76:103754.
doi: 10.1016/j.breast.2024.103754. Epub 2024 May 24.

Managing sexual health challenges in breast cancer survivors: A comprehensive review

Linda Cucciniello  1 , Federica Miglietta  2 , Valentina Guarneri  3 , Fabio Puglisi  4
Affiliations
Review

Managing sexual health challenges in breast cancer survivors: A comprehensive review

Linda Cucciniello et al. Breast. 2024 Aug.

Abstract

The significant advancements in breast cancer management have led to an increase in the prevalence of breast cancer survivors. Despite their efficacy, these treatments can cause a variable range of side effects, significantly deteriorating the patients' quality of life. Sexual dysfunction, and in particular the genitourinary syndrome of menopause, represent one of the major causes of quality-of-life impairment among breast cancer patients, potentially affecting treatment adherence and compliance. If in the general population, hypoestrogenism-related symptoms are typically managed through systemic or topical estrogen administration, this approach is contraindicated in breast cancer patients for the potential increased risk of disease recurrence, urging the investigation of alternative measures. The aim of this review is to summarize the most up-to-date pharmacological and non-pharmacological interventions, as well as supportive measures, available for the management of sexual dysfunctions in breast cancer patients and survivors.

Keywords: Breast cancer; Sexual dysfunctions; Survivorship.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Key factors influencing sexual health dysfunction in breast cancer patients.
Fig. 2
Fig. 2
Available treatment options for the management of genitourinary syndrome of menopause.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bluethmann S.M., Mariotto A.B., Rowland J.H. Anticipating the “silver tsunami”: prevalence trajectories and Co-morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25:1029–1036. doi: 10.1158/1055-9965.EPI-16-0133. - DOI - PMC - PubMed
    1. Cucciniello L., Garufi G., Di Rienzo R., Martinelli C., Pavone G., Giuliano M., et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome. Cancer Treat Rev. 2023;120 doi: 10.1016/j.ctrv.2023.102624. - DOI - PubMed
    1. Francis P.A., Pagani O., Fleming G.F., Walley B.A., Colleoni M., Láng I., et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–137. doi: 10.1056/NEJMoa1803164. - DOI - PMC - PubMed
    1. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (London, England) n.d.;365:60–62. 10.1016/S0140-6736(04)17666-6. - DOI - PubMed
    1. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092. doi: 10.1056/NEJMoa040331. - DOI - PubMed

MeSH terms